Colonoscopy

WellSpan Health expanding access to care across multiple parts of Lancaster County

Retrieved on: 
Thursday, May 18, 2023
Partnership, WellSpan Health, Former state routes in Pennsylvania, Health, Endoscopy, CDC, Patient, Colonoscopy, Air Methods, Nursing, Hospital

York, Pa., May 18, 2023 (GLOBE NEWSWIRE) -- To meet the rapidly growing demand for health care services across Lancaster County, WellSpan is expanding high-quality care options that are focused on convenience and a positive patient experience.

Key Points: 
  • York, Pa., May 18, 2023 (GLOBE NEWSWIRE) -- To meet the rapidly growing demand for health care services across Lancaster County, WellSpan is expanding high-quality care options that are focused on convenience and a positive patient experience.
  • At the core of WellSpan’s efforts to increase access to care in Lancaster will be a 34,000 square foot surgery center to be constructed in the CityGate Corporate Center.
  • In addition to the new surgery center, WellSpan will also be building an outpatient endoscopy center and expanding digestive health services in Brownstown.
  • “WellSpan Health is committed to ensuring our neighbors that call Lancaster County home have accessible and exceptional care,” said Stuccio.

EXACT SCIENCES AWARDS GRANTS TO 18 ORGANIZATIONS FOCUSED ON INCREASING COLORECTAL CANCER SCREENINGS

Retrieved on: 
Wednesday, May 17, 2023
University of Central Florida College of Medicine, Partnership, University, CRC, Education, Community, UCF, FOCUS, Public, Michigan State University College of Nursing, Cancer, Woman, Large intestine, Exact sciences, Organization, Death, Colorectal cancer, CHW, Patient, Risk, Colonoscopy, Disease, Motivation, FOCUS Program, Knowledge, Mortality, United, Alaska Natives, Exact Sciences (company), FDA, Life Matters Media, Pharmaceutical industry, Vaccine, Nursing, Life insurance, Interior design

Grant recipients are committed to improving uptake of colorectal cancer (CRC) screening and supporting affordable pathways to follow-up care for people who are medically underserved.

Key Points: 
  • Grant recipients are committed to improving uptake of colorectal cancer (CRC) screening and supporting affordable pathways to follow-up care for people who are medically underserved.
  • "Awareness and access are critical to increasing screenings, and Exact Sciences is honored to support these organizations that are driving screening uptake and addressing inequities within their communities."
  • Exact Sciences developed Cologuard®, the first and only FDA-approved, noninvasive, multi-target, stool-based DNA screening test that people can use at home.
  • The organization plans to implement a cancer awareness program focused on reducing CRC morbidity and mortality for people of color.

Huntsman Cancer Institute Grows to More than a Million Square Feet of State-of-the-Art Cancer Space with Opening of $178 Million Kathryn F. Kirk Center

Retrieved on: 
Wednesday, May 10, 2023
Nexus, Ceramic, Painting, University, Life, Treatment, Federation of Sovereign Indigenous Nations, Clinical trial, Breast, Cancer, Huntsman Cancer Institute, Kathryn, Hope, Research, Spencer, SALT, Doctor of Philosophy, Hospital, Beauty, MD, Patient, Collection, The Church of Jesus Christ of Latter-day Saints, Blood, Colonoscopy, Jon, Jewellery, Health, Mammography, Family, Church, Hugo Weaving, Disease, Saint, Dentistry, Pharmaceutical industry

SALT LAKE CITY, May 10, 2023 /PRNewswire/ -- Huntsman Cancer Institute at the University of Utah (the U), the only place in the region devoted to developing new treatments for cancer, announced the opening of the Kathryn F. Kirk Center for Comprehensive Cancer Care and Women's Cancers today.

Key Points: 
  • Huntsman Cancer Institute experts are among the best in the world at identifying cancers in their earliest stages when it's easier to treat.
  • "We are so grateful to our dedicated staff at Huntsman Cancer Institute for their countless hours helping plan and design this cutting-edge facility," says Mary Beckerle, PhD , CEO of Huntsman Cancer Institute.
  • "Many generous donors came together to make this latest expansion of Huntsman Cancer Institute possible," says Peter Huntsman , chairman and CEO of Huntsman Cancer Foundation .
  • Cancer care is truly comprehensive, and this new center will increase the impact of the Huntsman Cancer Institute Wellness and Integrative Health Center by 1,936 square feet.

AMEND PET AND ASSOCIATION OF SHELTER VETERINARIANS PARTNER TO EXPAND ACCESS TO FECAL MICROBIOTA TRANSPLANT FOR TREATING DIARRHEA IN SHELTER PETS

Retrieved on: 
Wednesday, May 10, 2023
Enema, Partnership, Dysbiosis, Diarrhea, Veterinarian, FMT, Trust, Animal, Patient, ASV, Dog, Pet, Colonoscopy, Health, Veterinary medicine, Management

SEATTLE, May 10, 2023 /PRNewswire/ -- Amend Pet ("the company"), a microbiome solutions company, today announced the launch of its partnership with the Association of Shelter Veterinarians (ASV) to provide ASV members affordable, easy-to-administer Fecal Microbiota Transplant Therapy (FMT) and microbiome testing to assess dogs for dysbiosis. FMT is a proven treatment for recurrent diarrhea in pets, but until now has been too labor intensive and costly for veterinarians to widely utilize.

Key Points: 
  • FMT is a proven treatment for recurrent diarrhea in pets, but until now has been too labor intensive and costly for veterinarians to widely utilize.
  • Amend Pet's FMT capsule device and testing solution allows veterinarians to prepare multiple transplant regimens in 5-10 minutes in their own facility from pet donors they know and trust.
  • "We are excited to support ASV Veterinarians who maximize limited resources to provide a vital service for countless animals", said Mike Goonewardene, CEO of Amend Pet.
  • "Our partnership with Amend Pet opens the door to innovative products and services in a vital area of care, digestive health, for animals residing in shelters across the country".

Universal DX Presents Data from Large, 1,000-patient, Multi-Cohort Study Proving 91% Sensitivity for Colorectal Cancer and 54% Sensitivity for Advanced Adenoma at 92% Specificity

Retrieved on: 
Tuesday, May 9, 2023
Biotechnology, Medical Devices, Health, Pharmaceutical, Oncology, Survival rate, Computational biology, Gastrointestinal disease, DNA, Methylation, CRC, Nucleic acid thermodynamics, CNV, NYU, New York University Grossman School of Medicine, Cancer, Research, Biomarker, Plasma, Senior lecturer, Patient, Machine learning, Colorectal cancer, Traditional serrated adenoma, Algorithm, Colonoscopy, Imperial College London, Universal, Neoplasm, MPH, III, Consultant, AA, Medical imaging, MD, Gastroenterology, Medicine

The findings offer an optimistic glimpse into the future of early-stage CRC detection and cancer prevention via AA detection through a simple blood test.

Key Points: 
  • The findings offer an optimistic glimpse into the future of early-stage CRC detection and cancer prevention via AA detection through a simple blood test.
  • “We have every reason to be positive about the future of early cancer detection based on these results,” said Christian Hense, COO at Universal DX.
  • In 2022, the company extended early-stage colorectal cancer detection to prognostics and stratification and demonstrated the analysis of microbiome signatures in plasma can assist in early detection of colorectal cancer .
  • Universal DX is on a pathway to cracking the code to early cancer detection.”
    The data will be presented at Digestive Disease Week , taking place in Chicago, May 6-9:

Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023

Retrieved on: 
Monday, May 8, 2023
Biotechnology, FDA, Infectious Diseases, Health, Pharmaceutical, Infection, Clostridioides difficile infection, Kidney disease, Ferring Pharmaceuticals, Gastrointestinal disease, Diarrhea, IBD, Safety, Clinical trial, Cancer, Multimedia, Abdominal pain, Ulcerative colitis, Yale School of Medicine, Inflammatory bowel disease, DDW, Incidence, Significance, Patient, Nature, Comorbidity, Colonoscopy, Nausea, AAT, Poster, Immunodeficiency, GI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Roger Hawkins (drummer), Food, PUNCH, Pharmaceutical industry

An additional analysis looked at microbiome compositional changes and clonal engraftment following treatment with REBYOTA.

Key Points: 
  • An additional analysis looked at microbiome compositional changes and clonal engraftment following treatment with REBYOTA.
  • In the pooled safety population (N=547), 18 patients were identified as having Crohn’s disease only and 38 had ulcerative colitis only.
  • Of the 56 patients evaluated, 39 patients (69.6%) received IBD-related medication at the time of REBYOTA administration.
  • Samples provided by REBYOTA-treated patients were assessed to determine if the species present after treatment were those present in the REBYOTA dose they received.

Iterative Health Announces Upcoming U.S. Availability of SKOUT®: Real-Time AI for Polyp Detection

Retrieved on: 
Thursday, May 4, 2023
Technology, Surgery, Medical Devices, Hospitals, Health Technology, Software, Health, Artificial Intelligence, Oncology, Software as a service, ADR, NYU, FTV, Provat Lakra, New York University Grossman School of Medicine, Fortive, Multimedia, Large intestine, Adenoma, Colorectal cancer, Incidence, Patient, Artificiality, Polyp (medicine), Randomized controlled trial, Colonoscopy, APC, Artificial intelligence, FDA, MPH, NYSE, Polyp, Medical imaging, Nursing, MD, Gastroenterology, Medicine

Iterative Health , a pioneer in precision-medicine technologies for gastroenterology, and Provation , the premier software and SaaS provider of clinical productivity and workflow automation solutions and a wholly-owned operating company of Fortive Corporation (NYSE: FTV), announced today the upcoming commercial availability of SKOUT, real-time artificial intelligence for polyp detection, in the second quarter of 2023.

Key Points: 
  • Iterative Health , a pioneer in precision-medicine technologies for gastroenterology, and Provation , the premier software and SaaS provider of clinical productivity and workflow automation solutions and a wholly-owned operating company of Fortive Corporation (NYSE: FTV), announced today the upcoming commercial availability of SKOUT, real-time artificial intelligence for polyp detection, in the second quarter of 2023.
  • SKOUT is indicated as a computer-aided detection tool to assist qualified and trained endoscopists in identifying potential colorectal polyps during colonoscopy examinations in adult patients undergoing colorectal cancer screening or surveillance.
  • This press release features multimedia.
  • SKOUT enhances procedure quality with increased adenoma detection, and reduces challenges in detecting certain polyp types, such as flat polyps and polyps in the proximal colon.1
    Preserving existing workflows.

Retrospective Analysis of Data Evaluating Safety and Efficacy of REBYOTA™ (fecal microbiota, live – jslm) in a Real-World Patient Population with Comorbidities and Risk Factors Published in Open Forum Infectious Diseases

Retrieved on: 
Thursday, May 4, 2023
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Infection, Ferring Pharmaceuticals, Diarrhea, IBD, Clinical trial, PSS, Urinary tract infection, Irritable bowel syndrome, Multimedia, Inflammation, Abdominal pain, Ulcerative colitis, Yale School of Medicine, Inflammatory bowel disease, Clostridioides difficile, Clostridioides difficile infection, Comorbidity, Patient, IBS, Risk, Colonoscopy, Variometer, Nausea, Bloating, AAT, Recurrence, Immunosuppression, Roger Hawkins (drummer), Safety, Pharmaceutical industry

The AAT program offered REBYOTA to adults not eligible for clinical trial participation or who needed additional treatment following study participation.

Key Points: 
  • The AAT program offered REBYOTA to adults not eligible for clinical trial participation or who needed additional treatment following study participation.
  • The primary objective was to evaluate the safety and tolerability of REBYOTA through six months after treatment.
  • The secondary objectives were to evaluate efficacy in preventing rCDI within eight weeks of treatment and sustained response for six months after treatment.
  • We are committed to ongoing research to help as many patients as possible who are living with recurrent C. diff infection.”

US Digestive Health Relocates Gastroenterologist Office from Brandywine to Join Affiliated Endoscopy Center in Downingtown, PA

Retrieved on: 
Tuesday, May 2, 2023
Gastroenterology, Endoscopy, Colonoscopy, Suite, National Association Medical Staff Services, Patient, Cancer, Colorectal cancer, Polyp (medicine), Pennsylvania Avenue, AI, Health, Polyp, Platinum, Nursing, MD

After the welcome ceremony, referring physicians and other attendees received guided tours of the two facilities, followed by a ribbon-cutting.

Key Points: 
  • After the welcome ceremony, referring physicians and other attendees received guided tours of the two facilities, followed by a ribbon-cutting.
  • The office space is located in Downingtown, Pennsylvania, at Mill Town Square, 150 East Pennsylvania Avenue, Suite 500, and the endoscopy center, formerly known as Brandywine Valley Endoscopy Center (BVEC), is conveniently located in Suite 320.
  • The newly relocated office supports diagnostic and therapeutic procedures for digestive diseases, while the endoscopy center features cutting-edge technology and advanced imaging equipment, offering a range of services, including colonoscopies and upper endoscopies.
  • “Patients in Downingtown will now have convenient, centralized access to industry-leading gastroenterology care and a state-of-the-art endoscopy center," said Dr. Frederic Meyers, founder of CCCE.

Olympus Announces FDA Clearance of New Endoscopy System and Compatible Endoscopes

Retrieved on: 
Tuesday, May 2, 2023
Xenon, Gastrointestinal disease, ASGE, Histology, TXI, Vein, Brightness, Duodenum, Coeliac disease, American Society for Gastrointestinal Endoscopy, Esophagus, Stomach, Colon, Capillary, BAI, DDW, Crohn's disease, RDI, Gastrointestinal tract, Rectum, Patient, Physician, Colorectal cancer, NBI, Colonoscopy, Observation, Texture, Diagnosis, Ulcer, FDA, GI, Maintenance, Society, Polyp, Medical imaging

CENTER VALLEY, Pa., May 2, 2023 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today the FDA clearance of the new EVIS X1 endoscopy system, along with two compatible gastrointestinal endoscopes: the GIF-1100 gastrointestinal videoscope indicated for use within the upper digestive tract including the esophagus, stomach, and duodenum; and the CF-HQ1100DL/I colonovideoscope indicated for use within the lower digestive tract including the anus, rectum, sigmoid colon, colon, and ileocecal valve.i

Key Points: 
  • The EVIS X1 endoscopy system features three new enhancements designed to assist physicians in visualizing GI bleeds and anatomical structures.
  • The proven optical-digital technology NBI™ (Narrow Band Imaging™) technology continues to be featured in this next-generation endoscopy system.
  • The EVIS X1 Endoscopy System will be on display and demonstrated in Olympus Booth #3820 at the DDW (Digestive Diseases Week) meeting in Chicago, May 7-9.
  • Information about the EVIS X1 Endoscopy System will be available here: info.olympusamericamarketing.com/X1 .